Congenital pharma emphasizes Anket® abstracts that were selected for the EHA 2025 congress

The portfolio of Innate includes several anchors^® Pharmaceutical candidates to combat several types of tumor and IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-Kir3dl2-Mab-lacutamab in an advanced form of cutaneous T cell lymphomas and peripheral T-cell lymphomas is developed, and anti-nkg2a-Mab Monalizumab is developed with astrazeneca with non-weak cell cancer.

In Budeneate Pharma, a trustworthy partner of biopharmaceutical companies such as Sanofi and Astrazeneca as well as leading research institutions to accelerate innovation, research and development for the benefit of patients.

In the innate pharmaceutical based in Marseille, France with a US office in Rockville, MD, is listed in the USA on Euronext Paris and Nasdaq.

Find out more about congenital pharmaceuticals at www.innate-pharma.com. Follow us under LinkedIn and X.

Information on innate pharmaceutical parts

Disclaimer for future -oriented information and risk factors

This press release contains certain forward-looking statements, including information within the Meaning of Applicable Securities Laws, including the private securities litigation Reform Act of 1995. The use of certain Words, included “anticipate,” “” “” “can,” “can,” ” “Estimate,” “Expect,” “May,” “Might,” “Potential,” Intend, “Should,” “” “or Similar Expressions, is intended to identify forward looking statements. Although the company believes that its expectations are based on adequate assumptions, these future -oriented statements are subject to numerous risks and uncertainties that can lead to the actual results differ significantly from the expected waste. Thesis Risk and Uncertainties Include, Among Other Things, The Uncertainties Inherent in Research and Development, Including Related to Safety, Progression of and Results From Its Ongoing and Planned Clinical Trials and Preclinical Studies, Review and Approvals Authorities of ITS Product Candidates, The Company's Reliance on Third Parties to Manufacture Its Product Candidates, The Company's Commercialization EFFORTS and the Company's Continued Ability to Raise Capital to Fund Its Development. For an Additional Discussion of Riscs and Uncertainties, which Could the Company's Actual Results, Financial Condition, Performance or Achievements to Differ From Those Contained In The Forward-Looking Statements, PLASE RISK FACTORS (“Facture DE RISQUE”) Section of the Universal Registration Document FILED with the French Financial Markets Authority (“AMF”), which is Available on the Amf Website Or on Innate Pharma's Website, and Public Filings and Reports Filed with the Us Securities and Exchange Commission (“Sec”), including the company's annual report on Form 31, 2024 Submissions and reports that were submitted to the AMF or the SEC or were published in other ways by the company. References to the company's website and the AMF website are only included for information, and the content contained therein or on this cannot be included in this press release by reference.

In view of the considerable uncertainties in these future -oriented statements, you should not consider these statements to be represented or guarantee by the company or another person who achieves the company in a certain time frame or even its goals and plans. The company assumes no obligation to publicly update future statements, be it based on new information, future events or in any other way, except as required by law.

This press release and the information contained here are no offer for sale or advertising for an offer for buying or subscribing to stocks in congenital pharmaceutical in a country.

Show source version on businesswire.com:

Contacts

For more information, please contact:

Investors
Congenital pharmaceutical
Henry Wheeler
Tel.: +33 (0) 4 84 90 32 88
Henry.wheeler@innate-pharma.fr

Media relationships
Newcap
Arthur Rouillé
Tel.: +33 (0) 1 44 71 00 15
innate@newcap.eu